Please find attached the notice of shareholders meeting scheduled on 1st September, 2026.

Date: 06th August, 2026 The Manager, BSE SME Platform Phiroze Jeejeebhoy Towers, Dalal St, Kala Ghoda, Fort, Mumbai, Maharashtra 400001 BSE Scrip Code: 542934 Subject: Notice of the 23rd Annual General Meeting of the Company and submission of Annual Report for the Financial Year 2025-26. Dear Sir/ Madam, Pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial year 2025-26 along with the Notice convening the 23rd Annual General Meeting scheduled to be held on Tuesday, 1st September, 2026 at 04:00 P.M. (IST) at 323-F, Bhagat Bhuvan, Dr. Ambedkar Road, Matunga (East), Mumbai-400019, Maharashtra, India is being sent through electronic mode to the shareholders of the Company. The aforesaid Annual Report is also available on website of the Company at www.cbcpharma.com and website of stock Exchange i.e., BSE India Limited at www.bseindia.com. Kindly take the above information on your records. Yours faithfully, FOR CHANDRA BHAGAT PHARMA LIMITED HEMANT C BHAGAT MANAGING DIRECTOR DIN: 00233530 Notice Content Page No. Message of Managing Director 5 Notice, Proxy Form and Attendance Slip 6 Director’s Report 27 Annexures to Director’s Report Management Discussion and Analysis Report (Annexure – A) 41 Details pertaining to remuneration (Annexure –B) 47 Form No. AOC-2 (Annexure –C) 49 Secretarial Audit Report (Annexure – D) 51 Financial Statement Standalone Financials Auditor’s Report 57 Financial Statements 67 Corporate Information Board of Directors Statutory Auditors Mr. Hemant C Bhagat M/s. A Y & Company., Chartered Accountants, Chairman cum Managing Director 404, ARG Corporate Park, Gopal Bari, Ajmer Road, Jaipur- 302006, Rajasthan, India Pranav H Bhagat Whole Time Director Secretarial Auditors Prachi Pranav Bhagat M/s. M/s. CS Amit Dharmani & Associates, Company Director Secretary Ravindra Gajanan Awati Banker Non-Executive Independent Director Axis Bank Abha Praveen Doshi Registered Office Non-Executive Independent Director 323-F, Bhagat Bhuvan, Dr. Ambedkar Road, Matunga (East), Mumbai- 400019, Maharashtra, India Key Managerial Personnel Registrar & Share Transfer Agent Prachi Pranav Bhagat Chief Financial Officer MUFG Intime India Private Ltd. (Formerly Link Intime India Private Ltd) Rajni Dawani Company Secretary & Compliance Officer CIN: U67190MH1999PTC118368 C-101, Embassy 247, L. B. S. Marg, Vikhroli (West), Mumbai - 400083 Contact Us Investors Email-Id: compliancecbc@gmail.com Website: www.cbcpharma.com Equity Shares ISIN code: INE07QQ01016 Listed on Stock Exchange BSE SME platform Corporate Identification Number: L24230MH2003PLC139534 MANAGING DIRECTOR MESSAGE TO SHAREHOLDERS Dear Esteemed Stakeholders, Good day to all of you. On behalf of the Board of Directors, it is my privilege to welcome you to the Annual General Meeting of Chandra Bhagat Pharma Limited. I would like to express my sincere gratitude for your continued trust and unwavering support. The financial year 2025–26 has been one of meaningful progress, resilience, and transformation, despite operating in a dynamic and often challenging external environment. At Chandra Bhagat Pharma Limited, our commitment to delivering long-term value remains steadfast — anchored in strategic growth, operational excellence, and responsible corporate governance. Over the past year, we have made significant strides in executing our strategic initiatives, and I am pleased to share some key highlights with you: Governance and Compliance We continue to uphold the highest standards of corporate governance, transparency, and regulatory compliance. Our Board remains deeply engaged in shaping our strategic direction and overseeing risk management practices to safeguard the interests of all stakeholders. Outlook As we look ahead, we remain cautiously optimistic about the broader economic outlook. With a clearly defined strategic roadmap, a resilient business model, and a passionate leadership team, we are well- positioned to seize emerging opportunities and navigate potential headwinds with confidence and agility. In closing, I wish to extend my heartfelt appreciation to our employees, customers, suppliers, partners, and shareholders. Your belief in our vision and your continued support fuel our pursuit of innovation, excellence, and sustainable growth. With your continued partnership, I am confident that Chandra Bhagat Pharma Limited will scale new heights in the years to come. Thank you once again. NOTICE IS HEREBY GIVEN THAT THE 23rd ANNUAL GENERAL MEETING OF THE MEMBERS OF CHANDRA BHAGAT PHARMA LIMITED WILL BE HELD ON TUESDAY, 01st DAY OF SEPTEMBER, 2026 AT REGISTERED OFFICE OF THE COMPANY AT 323-F, BHAGAT BHUVAN, DR. AMBEDKAR ROAD, MATUNGA (EAST), MUMBAI-400019, MAHARASHTRA, INDIA AT 04:00 P.M. Ordinary Business: 1. ADOPTION OF ANNUAL ACCOUNTS: To receive, consider and adopt the Directors Report, Profit & Loss Account, Cash Flow Statement, Notes to Account for the year ended March 31st, 2026 and the Balance Sheet as on that date and the Reports of the Statutory Auditors, thereon. 2. RE-APPOINTMENT OF MR. PRANAV HEMANT BHAGAT (DIN: 00156362), LIABLE TO RETIRE BY ROTATION, WHO HAS OFFERED HIMSELF FOR RE-APPOINTMENT: To appoint a director in place of Mr. Pranav Hemant Bhagat (DIN: 00156362) who retires by rotation and being eligible, offers himself for re-appointment. Special Businesses: ITEM NO. 3: TO INCREASE IN THE AUTHORIZED SHARE CAPITAL OF THE COMPANY: To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 61 and other applicable provisions, if any, of the Companies Act, 2013 and the Rules framed thereunder, and other applicable laws, and subject to such other approvals as may be required in this regard, the consent of the members of the Company be and is hereby accorded for increase in the Authorised Share Capital of the Company from existing Rs. 8,50,00,000/- (Rupees Eight Crores Fifty Lakhs only) divided into 85,00,000 (Eighty-Five Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each to Rs. 15,00,00,000/- (Rupees Fifteen Crores only) divided into 1,50,00,000 (One Crore Fifty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each by creation of additional Rs. 6,50,00,000/- (Rupees Six Crores Fifty Lakhs only) divided into 65,00,000 (Sixty-Five Lakhs) Equity shares of Rs. 10/- (Rupees Ten only) each ranking pari passu in all respects with the existing Equity Shares of the Company as per the Memorandum and Articles of Association of the Company. RESOLVED FURTHER THAT pursuant to Section 13 and all other applicable provisions, if any, of the Companies Act, 2013, and the Rules framed thereunder, and other applicable laws, and subject to such other approvals as may be required in this regard, the consent of the members of the Company be and is hereby accorded, for alteration of existing Clause V of the Memorandum of Association of the Company by substituting the following in its place: “The Authorised Capital of the Company is Rs. 15,00,00,000/- (Rupees Fifteen Crores only) divided into 1,50,00,000 (One Crore Fifty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each with power to increase/reduce/alter/divide the same in such manner as may be permitted by the Act or as provided by the Articles of Association of the Company.” RESOLVED FURTHER THAT any Director, the Chief Financial Officer, and the Company Secretary & Compliance Officer of the Company be and are hereby severally authorized to take such steps and to do all such acts, deeds, matters and things as may be required to give effect to the foregoing resolution.” ITEM NO. 4: TO CONSIDER AND APPROVE ISSUANCE OF UPTO 66,00,000 CONVERTIBLE WARRANTS ON A PREFERENTIAL BASIS TO PROMOTERS AND NON-PROMOTERS FOR CONSIDERATION IN CASH: To consider and if thought fit, to pass, with or without modif [Showing first 8,000 characters — download PDF for full document]